Drugs / Songling Xuemaikang Capsules
Songling Xuemaikang Capsules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06093932 | Apr → Dec 2024 overdue | essential hypertension | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Songling Xuemaikang Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06093932 ↗ |
| Known as | SLXMKC | “Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension” NCT06093932 ↗ |
| Known as | Songling Xuemaikang capsule | “Songling Xuemaikang capsule (SXC), a Chinese patent medicine, has been preliminarily demonstrated the benefits of lowering blood pressure (BP) and associated hypertensive symptoms.” PMID 40770317 ↗ Aug 2025 |
| Known as | SXC | “Songling Xuemaikang capsule (SXC), a Chinese patent medicine, has been preliminarily demonstrated the benefits of lowering blood pressure (BP) and associated hypertensive symptoms.” PMID 40770317 ↗ Aug 2025 |
| Modality | Traditional medicine (herbal / TCM) | “Songling Xuemaikang capsule (SXC), a Chinese patent medicine” PMID 40770317 ↗ Aug 2025 |